CureVac (CVAC.US) loses more than 30% today after a German court quashed a company's patent. As Reuters analysis reports, the patent in question is one of several intellectual property titles that CureVac claims were infringed in ongoing legal proceedings. The patent was also the basis of a patent violation lawsuit by CureVac against its market rival and mRNA vaccines producer, BioNTech (BNTX.US), in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. As presiding judge in Germany's patent court, said in his ruling after a hearing, the patent is now invalid for the Germany territory. Biontech's shares are up 2% today. CureVac'smRNA-based COVID-19 vaccine didn't bring any significant cash from sales. At the same time, BioNTech / Pfizer collaboration made more than $40 billion in combined vaccines sales in 2021 and 2022.
Source: xStation5
US OPEN: Selling pressure eases, Anthropic gives back post-IPO gains
Market Wrap: Global stocks post 7th consecutive session of losses, Anthropic failed to reassure the market (20.11.2026)
Morning Wrap: Stock Indices and Metals Extend Their Declines 📉 (20.11.2026)
Daily Summary: Anthropic Steals the Show on Wall Street. Record IPO, but Market Optimism Fades